Patterns of Weight Change Preceding Hospitalization for Heart Failure

Sarwat I. Chaudhry, MD; Yongfei Wang, MS; John Concato, MD, MPH; Thomas M. Gill, MD; Harlan M. Krumholz, MD, SM

Background—Weight gain is used by disease-management programs as a marker of heart failure decompensation, but little information is available to quantify the relationship between weight change in patients with heart failure and the risk for imminent hospitalization.

Methods and Results—We conducted a nested case-control study among patients with heart failure referred to a home monitoring system by managed care organizations. We matched 134 case patients with heart failure hospitalization to 134 control patients without heart failure hospitalization on the basis of age, sex, duration of home monitoring, heart failure severity, and baseline body weight. Compared with control patients, case patients experienced gradual weight gain beginning ≈30 days before hospitalization; changes in daily weight between case and control patients were statistically significant (P<0.001). Within the week before hospitalization, when weight patterns in case and control patients began to diverge more substantially, mean increases of more than 2 and up to 5 pounds, more than 5 and up to 10 pounds, and more than 10 pounds (relative to time of enrollment in the monitoring system) were associated with matched adjusted odds ratios for heart failure hospitalization of 2.77 (95% confidence interval 1.13 to 6.80), 4.46 (95% confidence interval 1.45 to 13.75), and 7.65 (95% confidence interval 2.22 to 26.39), respectively, compared with mean increases of 2 pounds or less.

Conclusions—Increases in body weight are associated with hospitalization for heart failure and begin at least 1 week before admission. Daily information about patients’ body weight identifies a high-risk period during which interventions to avert decompensated heart failure that necessitates hospitalization may be beneficial. (Circulation. 2007;116:1549-1554.)

Key Words: heart failure ■ prognosis ■ disease management ■ epidemiology

Systems to enhance remote monitoring of patients’ clinical status have the potential to improve the care and outcomes of heart failure patients. These monitoring systems, which collect and transmit daily clinical information, are being used more frequently and in diverse settings.1-3 Moreover, the Centers for Medicare and Medicaid Services is implementing a widespread demonstration project involving >300 000 patients that mandates use of this surveillance strategy.4 The underlying clinical science defining the prognostic importance of surveillance information, however, has not been developed. For these systems to achieve their promise, the utility of the collected information must be defined. In particular, weight gain has long been regarded by clinicians as a marker of heart failure decompensation, but studies have not defined the pattern of daily weight change that precedes hospitalizations for heart failure.

Editorial p 1526
Clinical Perspective p 1554

Accordingly, we evaluated data from a group of heart failure patients who were weighing themselves daily as part of a disease-management remote-monitoring system. The goals of the present study were to describe trends in weight preceding hospitalization for heart failure and to determine whether increasing weight is a risk factor for imminent heart failure hospitalization. Equipped with such information, clinicians could make better management decisions to potentially avert hospitalization among their patients with decompensated heart failure.
Patients enrolled in the home monitoring program were instructed to weigh themselves using the digital scale at the same time each morning after urinating, before eating or drinking, and wearing the same amount of clothing. Any weight gain of at least 5 pounds during the course of 3 days prompted an automated report that was faxed to the patient’s physician, who could then institute a change in therapy or take other appropriate action. The median rate of missing data for daily weights was 4%, with an interquartile range of 0% to 15%, and did not differ between case and control patients. Telephone interviews with patients were conducted by Alere staff on enrollment and disenrollment from the system. Patients were queried about medication use, comorbidities, and heart failure and non–heart failure hospitalizations. (Patients were asked what the primary reason for hospitalization was, and hospitalizations were then classified as “heart failure” or “non–heart failure” using this information.) Patients were also contacted when 2 consecutive days of using the monitoring system were missed, to enforce adherence or obtain information about hospitalization.

Statistical Analyses
For descriptive purposes, we compared medical conditions (hypertension, coronary artery disease, diabetes mellitus, stroke/transient ischemic attack, and chronic obstructive pulmonary disease) and use of medications (angiotensin-converting enzyme inhibitors and β-blockers) between case and control patients at the time of enrollment into the monitoring system using the Fisher exact test. We did not impute missing data for weight, and other fields in the analyses did not have missing data.

Daily weight change, calculated by subtracting baseline weight (first weight obtained on entry into the monitoring system) from weight on a given day, was compared between case and control patients. Visual inspection was used initially to evaluate timing of weight change among study participants. To assess the specificity of the results, daily weight changes before non–heart failure hospitalizations were also compared; we assembled 688 cases with non–heart failure hospitalizations and then matched an equal number of control patients. Case patients were identified by the first occurrence of non–heart failure hospitalization during the 18-month follow-up period. For each case, we randomly selected a control patient from among all participants who had not been admitted to the hospital up to the time of the matched case patient’s hospitalization. Case and control patients were matched on the same criteria used in the analyses of heart failure hospitalizations (same month in which patients started the monitoring system, similar baseline body weight, similar age, same sex, and same severity of heart failure).

We evaluated the independent effect of antecedent weight change within a 1-week period before heart failure hospitalization (based on case patients) in both unadjusted and adjusted analyses using conditional logistic regression techniques for matched data. All comorbid conditions and medications listed in Table 1 were evaluated in the adjusted analyses: hypertension, coronary artery disease, diabetes mellitus, stroke/transient ischemic attack, chronic obstructive pulmonary disease, use of angiotensin-converting enzyme inhibitors, and use of β-blockers. Average weight change within 1 week before heart failure hospitalization was categorized as an increase of 2 pounds or less (including weight loss), >2 and up to 5 pounds, >5 and up to 10 pounds, and >10 pounds. For each of these categories, dummy variables were created (with “2 pounds or less” as the reference group) when entered into the conditional logistic regression model. We also evaluated average weight change within 1 week before hospitalization as a continuous variable in a separate model.

All analyses were conducted with SAS software version 9.1 (SAS Institute, Cary, NC). Alere Medical Inc provided the data but had no role in the design and conduct of the study; management, analysis, and interpretation of the data; or preparation, review, and approval of the manuscript. The Yale Human Investigations Committee approved the study protocol.

The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results

As shown in Table 1, the mean age of the present study population was 74 years; 55% of patients were female; the mean length of participation in the monitoring system was 291 days; and 97% had NYHA class III heart failure. Case and control patients were similar with regard to the use of angiotensin-converting enzyme inhibitors and the presence of comorbid conditions, but more case patients than control patients were prescribed β-blockers. Of the 134 cases, 125 patients had only 1 hospitalization for heart failure, 5 had 2 hospitalizations, and 4 had 3 hospitalizations. None of the control patients experienced hospitalization.

Figure 1 shows the daily weight changes during the time preceding heart failure hospitalization among case and control patients. Each group experienced a slight decline in average weight (−1 pound) from enrollment to 45 days before hospitalization. Patterns in daily weight change were relatively similar until ≈30 days before hospitalization, at which point the weight pattern of the case patients began to diverge from that of the control patients. At ≈1 week before hospital admission, the weight gain in the case patients began to increase markedly, whereas the control patients had relatively stable weight (average 1- to 2-pound loss compared with baseline weight). The difference in daily weight changes between case and control patients within 30 days before (case) hospitalization was statistically significant (P<0.001).

When non–heart failure hospitalization case and control patients were considered as a group, the average age was 73 years, 53% were female, and 94% had NYHA class III heart failure. Case and control patients were well matched on baseline characteristics (data not shown) with only 1 exception: The proportion of patients with NYHA class IV heart failure was greater in the case patients (2.9%) than in the control patients (0.9%; P=0.006). The patterns of weight change observed before non–heart failure hospitalization were similar in case and control patients; as shown in Figure 2, weights were relatively constant in both case and control patients before non–heart failure hospitalization.

Table 2 shows adjusted, matched odds ratios (ORs) of heart failure hospitalization based on weight gain within the prior 7 days, accounting for comorbid conditions and medication use (with weight gain of 2 pounds or less used to define the reference group). The 7-day interval was chosen on the basis of data presented in Figure 1, which demonstrated rapid weight gain among case patients during this time. Relative to the time of enrollment, a weight gain of >2 and up to 5 pounds was associated with an adjusted OR of 2.77 (95% confidence interval [CI] 1.13 to 6.80) for heart failure hospitalization. The strength of the association increased with increasing amounts of weight gain, so that a weight gain of

<table>
<thead>
<tr>
<th>TABLE 1. Baseline Characteristics of Study Population</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>Total (n=268)</td>
</tr>
<tr>
<td>-----------------------------------------------------</td>
</tr>
<tr>
<td>Mean age, y (SD)</td>
</tr>
<tr>
<td>Sex, female, %</td>
</tr>
<tr>
<td>Duration of monitoring, d</td>
</tr>
<tr>
<td>NYHA class, %</td>
</tr>
<tr>
<td>I</td>
</tr>
<tr>
<td>II</td>
</tr>
<tr>
<td>III</td>
</tr>
<tr>
<td>IV</td>
</tr>
<tr>
<td>Prescribed ACEI, %</td>
</tr>
<tr>
<td>Prescribed β-blocker, %</td>
</tr>
<tr>
<td>Hypertension, %</td>
</tr>
<tr>
<td>Coronary artery disease, %</td>
</tr>
<tr>
<td>Diabetes mellitus, %</td>
</tr>
<tr>
<td>Stroke/TIA, %</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease, %</td>
</tr>
</tbody>
</table>

ACEI indicates angiotensin-converting enzyme inhibitor; TIA, transient ischemic attack.

Figure 1. Daily weight change before heart failure hospitalization: cases vs controls. n=268. "Days" on the x-axis denotes days before hospital admission in case patients. The difference in daily weight changes between case and control patients within 30 days before (case) hospitalization was statistically significant (P<0.001) on the basis of a generalized linear model with daily weight change as the dependent variable.
>5 and up to 10 pounds had an adjusted, matched OR of 4.46 (95% CI 1.45 to 13.75) and a gain of >10 pounds had an adjusted, matched OR of 7.65 (95% CI 2.22 to 26.39) for heart failure hospitalization. The adjusted, matched OR of hospitalization for unknown weight (N=14) was 1.07 (95% CI 0.31 to 3.68). In a separate regression model that assessed weight as a continuous variable, the matched OR for heart failure hospitalization was 1.07 (95% CI 1.02 to 1.11) for each additional pound of weight gain.

**Discussion**

We have demonstrated that clinically important increases in body weight begin at least 1 week before hospitalization for heart failure. Moreover, during this time period, the risk of heart failure hospitalization increases in a monotonic fashion with increasing amounts of weight gain. In contrast, weight gain was not observed before hospitalization for causes other than heart failure. The present study represents basic clinical research that generates evidence to guide decision making for patients with diastolic and systolic heart failure. Most studies that have assessed heart failure hospitalization rates have used invasive measurements of thoracic impedance and pulmonary artery pressures, although the published literature does not allow for direct comparisons with the present data. Heart failure is the most frequent reason for hospitalization among older patients, with direct hospital costs of more than $15.4 billion each year. The burden that heart failure hospitalization imposes on patients and their caregivers is also substantial. The present results, which support current recommendations from professional groups about the importance of self-weighing for heart failure patients, indicate that clinicians have an opportunity to intervene (eg, by increasing diuretic doses) and possibly avert hospitalization.

The “real-world” applicability of the results of the present study is reflected by data that come from actual patients participating in a home monitoring system, rather than a clinical trial with strict inclusion-exclusion criteria and complex follow-up procedures. Similar to heart failure patients seen in clinical practice, the majority of study participants were elderly. The validity of the present results is strengthened by the lack of association between weight gain and hospital admission for reasons other than heart failure and by the small amount of missing data on body weight. Importantly, the present analyses were matched on, and adjusted for, potential confounding factors that could have introduced bias, including baseline body weight.

Participation in the home monitoring system was voluntary, and we do not have information about the number of patients who declined participation; it is possible that the present results were affected by patients’ refusal to participate. Information was not available about type of heart failure (systolic versus diastolic) or presence of renal dysfunction, and it is possible that differences in these important clinical characteristics contributed to the weight patterns observed and hospitalization rates. Recent work suggests, however, that the rate of heart failure hospitalization is similar in patients with diastolic and systolic heart failure. Most patients in the present study had NYHA class III heart failure, which reflects the distribution of heart failure severity among patients participating in the monitoring system. Patients with NYHA class I and II heart failure may not have been deemed sick enough to justify the cost of the monitoring system.

**TABLE 2.** Conditional Logistic Regression Models of Heart Failure Hospitalization (n=240)

<table>
<thead>
<tr>
<th>Weight Gain, lbs</th>
<th>Case Patients, n (%)</th>
<th>Control Patients, n (%)</th>
<th>Matched Unadjusted OR (95% CI)</th>
<th>Matched Adjusted OR (95% CI)</th>
<th>Adjusted P</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;2</td>
<td>65 (54)</td>
<td>92 (77)</td>
<td>Reference group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;2 up to 5</td>
<td>21 (18)</td>
<td>16 (13)</td>
<td>2.40 (1.05–5.45)</td>
<td>2.77 (1.13–6.80)</td>
<td>0.026</td>
</tr>
<tr>
<td>&gt;5 up to 10</td>
<td>17 (14)</td>
<td>8 (7)</td>
<td>3.81 (1.35–10.77)</td>
<td>4.46 (1.45–13.75)</td>
<td>0.009</td>
</tr>
<tr>
<td>&gt;10</td>
<td>17 (14)</td>
<td>4 (3)</td>
<td>5.65 (1.81–17.65)</td>
<td>7.65 (2.22–26.39)</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Weight gain is during 1 week preceding hospitalization of case patients. Results were adjusted for comorbid conditions and the medications shown in Table 1.
whereas those with NYHA class IV heart failure may have been deemed too sick to benefit from this system. Whether the present results may be generalized to patients with mild or severe heart failure is therefore uncertain.

Information was not available on how clinicians used the weight data, including attempts that may have been made to address weight gain (such as increasing diuretic dosage). It is possible that patients who experienced a significant weight gain but were not yet ill enough to require hospitalization had an increase in their diuretic dosage or received some other type of intervention. Such interventions would, however, bias the study toward a null finding. Alternatively, it is possible that weight gain played a role in the decision for hospitalization, but it seems unlikely that clinicians would hospitalize patients solely because of weight gain, without other signs and symptoms of clinical decompensation. Whatever impact clinicians’ review of these data may have had on the results, significant differences between case and control patients in weight change were still observed. It is probable that the association between weight gain and hospitalization would be even stronger for patients in whom weight data were not being reviewed, and responded to with intervention, by clinicians.

The outcome in the present study (ie, heart failure hospitalization), was assessed by a nurse employed by Alere, Inc, during telephone interviews with patients. We do not have data to validate the accuracy of the outcome assessment, but a recent report suggests that concordance between self-reported and claims-based hospitalizations is high.15 Although all patients using the monitoring system were contacted via telephone by Alere staff to assess the outcomes used in the present study, we do not have data on the completeness of follow-up (ie, how often patients could not be reached to ascertain the outcome).

These data demonstrate that, on average, weight gain begins in a gradual fashion at least 1 week before heart failure hospitalization, but the present findings do not indicate that all admissions are preceded by weight gain. Some patients would have certainly experienced sudden decompensation with “flash” edema. For these episodes of decompensation, remote monitoring may prove less effective in averting hospitalization. In addition to weight gain, patients with heart failure may experience a range of other symptoms as manifestations of heart failure decompensation, including shortness of breath, fatigue, and leg swelling. The relative prognostic utility of such symptoms compared with body weight should be investigated in future studies.

Frequent monitoring of heart failure patients’ clinical status, specifically their body weights, can alert clinicians to the early stages of heart failure decompensation. By focusing on weight changes, clinicians would be well positioned to implement interventions that could prevent decompensation of heart failure that necessitates hospitalization. To determine whether this type of monitoring system can improve outcomes, 2 study authors (SIC and HMK) are currently conducting a multicenter randomized, controlled trial that implements daily remote monitoring of body weight. Any weight gain >2 pounds triggers clinical assessment and potential intervention, including dietary advice, medication adjustment, and clinic or emergency department visit. The intervention is being implemented and all outcomes are being assessed during the 6 months after hospitalization for heart failure decompensation. More than 1600 patients from 20 sites across the country will be enrolled, which makes this one of the largest studies of remote monitoring to date. Systems to facilitate frequent monitoring of heart failure patients’ clinical status have potential for improving the care and outcomes of patients with heart failure, but the emerging field of remote monitoring must be informed by evidence to guide clinicians in decision making.

Sources of Funding

Dr Krumholz is currently the principal investigator of a National Heart, Lung, and Blood Institute–funded R01 (R01-HL080228) examining telemonitoring in patients with heart failure, which provides salary support for Dr Chaudhry. Dr Gill is the recipient of a Midcareer Investigator Award in Patient-Oriented Research (K24 AG021507) from the National Institute on Aging.

Disclosures

Alere Medical Inc provided the data but had no role in the design and conduct of the study; management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. Dr Krumholz serves on the Advisory Board for Alere Medical Inc but does not have equity in the company. Dr Krumholz has research contracts with the Colorado Foundation for Medical Care and the American College of Cardiology, serves on the advisory boards for Amgen and UnitedHealthcare, is a subject matter expert for VHA, Inc, and is editor-in-chief of Journal Watch Cardiology of the Massachusetts Medical Society. The remaining authors report no conflicts.

References


**CLINICAL PERSPECTIVE**

Systems to enhance remote monitoring of patients’ clinical status have the potential to improve the care and outcomes of patients with heart failure. Weight gain has long been recognized by clinicians as a marker of heart failure decompensation, but little information is available to quantify the relationship between weight change in patients with heart failure and the risk for imminent hospitalization. Accordingly, we evaluated data from a group of heart failure patients who were weighing themselves daily as part of a disease-management remote-monitoring system. Using a nested case-control study design, we matched 134 case patients with heart failure hospitalization to 134 control patients without heart failure hospitalization. The results demonstrate that increases in body weight are associated with hospitalization for heart failure and begin at least 1 week before admission. Within the week before hospitalization, the risk of heart failure hospitalization increases in a monotonic fashion with increasing amounts of weight gain. Any weight gain of $\geq 2$ pounds is associated with increased risk of heart failure hospitalization. Our results indicate that weight gain is an important risk factor for hospitalization within a relatively short time period. Daily information about patients’ body weight can alert clinicians to patients who are at high risk for hospitalization on the basis of weight gain. Equipped with this information, clinicians can implement interventions to try to avert hospitalization.

Go to http://cme.ahajournals.org to take the CME quiz for this article.
Patterns of Weight Change Preceding Hospitalization for Heart Failure
Sarwat I. Chaudhry, Yongfei Wang, John Concato, Thomas M. Gill and Harlan M. Krumholz

*Circulation*. 2007;116:1549-1554; originally published online September 10, 2007; doi: 10.1161/CIRCULATIONAHA.107.690768
*Circulation* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2007 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/116/14/1549

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Circulation* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to *Circulation* is online at:
http://circ.ahajournals.org//subscriptions/